Table 3 Sensitivity, specificity, positive and negative predictive values of mesothelin and midkine in differentiating malignant mesothelioma from other diseases
| Â | Malignant mesothelioma vs metastatic cancers | Malignant mesothelioma vs benign asbestos pleurisy | Malignant mesothelioma vs benign pleural diseases | Malignant mesothelioma vs Pleural diseases other than malignant mesothelioma |
|---|---|---|---|---|
Mesothelin | ||||
 AUC (95% CI) | 0.68 (0.60-0.75) | 0.78 (0.69-0.85) | 0.73 (0.64-0.81) | 0.71 (0.64-0.77) |
 Sensitivity (%) (95% CI) | 51.6 (43.6-59.6) | 51.6 (42.5-60.7) | 51.6 (42.7-60.5) | 51.6 (44.6-58.6) |
 Specificity (%) (95% CI) | 71.4 (64.2-78.6) | 85.0 (78.5-91.5) | 85.2 (78.9-91.5) | 77.7 (71.9-83.5) |
 PPV (%) (95% CI) | 75.4 (68.5-82.2) | 94.2 (89.9-98.5) | 92.5 (87.8-97.2) | 68.1 (61.6-74.6) |
 NPV (%) (95% CI) | 46.5 (38.5-54.5) | 27.0 (18.9-35.1) | 33.3 (24.9-41.7) | 63.5 (56.8-70.2) |
Midkine | ||||
 AUC (95% CI) | 0.52 (0.44-0.60) | 0.69 (0.60-0.78) | 0.54 (0.44-0.63) | 0.52 (0.45-0.59) |
 Sensitivity (%) (95% CI) | 61.1 (53.3-68.9) | 61.1 (52.2-70.0) | 61.1 (52.5-69.8) | 61.1 (54.3-67.9) |
 Specificity (%) (95% CI) | 41.1 (33.3-48.9) | 75.0 (67.1-82.9) | 48.1 (39.3-57.0) | 49.5 (42.5-56.5) |
 PPV (%) (95% CI) | 63.7 (58.0-71.4) | 92.1 (87.2-97.0) | 80.6 (73.6-87.6) | 52.7 (45.7-60.0) |
 NPV (%) (95% CI) | 38.3 (30.5-46.1) | 28.8 (20.5-37.1) | 26.0 (18.2-33.8) | 58.0 (51.1-64.9) |
Mesothelin + Midkine | ||||
 AUC (95% CI) | 0.59 (0.51-0.67) | 0.83 (0.75-0.90) | 0.65 (0.56-0.74) | 0.73 (0.66-0.79) |
 Sensitivity (%) (95% CI) | 88.4 (80.2-94.1) | 88.42 (80.2-94.1) | 100.0 (96.2-100.0) | 80.0 (70.5-87.5) |
 Specificity (%) (95% CI) | 32.7 (20.7-46.7) | 77.78 (52.4-93.6) | 0 (0.0-12.8) | 58.8 (48.6-68.5) |
 PPV (%) (95% CI) | 69.4 (60.4-77.5) | 95.5 (88.7-98.8) | 77.9 (69.5-84.9) | 64.4 (55.1-73.0) |
 NPV (%) (95% CI) | 62.1 (42.3-79.3) | 56.0 (34.9-75.6) | 0 (0-0) | 75.9 (65.0-84.9) |